In our study, patients were divided into different groups depending on the brain tumor’s histopathological subtypes and tumor grade, finding a higher rate of IDH1 mutation (AF%) in the diffuse astrocytoma, glioblastoma and oligodendroglioma. This evidence concerns the gene IDH1 and neoplasm.